The BLOC1S6 antibody targets the BLOC1S6 protein, a subunit of the Biogenesis of Lysosome-related Organelles Complex 1 (BLOC-1). This multisubunit protein complex is critical for the formation and trafficking of lysosome-related organelles (LROs), such as melanosomes, platelet dense granules, and synaptic vesicles. BLOC1S6. also known as Pallidin, plays a role in membrane protein sorting and vesicle biogenesis, particularly in specialized cell types like melanocytes and neurons. Mutations in BLOC1S6 are linked to Hermansky-Pudlak syndrome (HPS), a rare genetic disorder characterized by oculocutaneous albinism, bleeding diathesis, and lysosomal dysfunction. Antibodies against BLOC1S6 are essential tools for studying the molecular mechanisms underlying LRO biogenesis, protein trafficking pathways, and HPS pathogenesis. They enable detection of BLOC1S6 expression via techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding in the identification of protein localization and interactions within the BLOC-1 complex. Research using these antibodies has contributed to understanding how BLOC-1 dysfunction disrupts cellular processes, offering insights into therapeutic strategies for HPS and related lysosomal disorders. Commercial BLOC1S6 antibodies are typically validated for specificity and sensitivity, ensuring reliability in both diagnostic and experimental contexts.